U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07625514) titled '24-Week Recurrence Rate of Gout Following Firsekibart Treatment' on May 24.
Brief Summary: Study Objective: To evaluate the 24-week recurrence rate and safety of Firsekibart in patients with acute gouty arthritis in a real-world clinical setting.
Study Methods: This study utilizes a multicenter, prospective, observational, real-world study design. The study plans to enroll all cases that receive Firsekibart for the first time and meet the inclusion and exclusion criteria between March 1, 2026, and February 28, 2029, with a follow-up period of 24 weeks. This study will not intervene in clinical treatment regimens; it will solely reco...